Tag: Pakistan

Nyxoah Announces Inaugural Investor & Analyst Meeting

Mont-Saint-Guibert, Belgium – February 21, 2023, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will host its inaugural Investor & Analyst Meeting on March 23, 2022, from 4:00pm to 7:00pm ET.

The event, which will be held at Nyxoah’s New York City offices, will include a business update from the Company’s senior management and presentations from key opinion leaders in the field of obstructive sleep apnea. The meeting will conclude with a Q&A session, followed by a reception.

Investors interested in attending the meeting may do so by registering for the event at the following link: Nyxoah Investor & Analyst Meeting 2023 (office.com). A live and archived webcast of the event will be available on the Company’s investor relations website at https://investors.nyxoah.com/events.

About Nyxoah
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA). Nyxoah’s lead solution is the Genio® system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.

Following the successful completion of the BLAST OSA study, the Genio® system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company is currently conducting the DREAM IDE pivotal study for FDA and US commercialization approval.

For more information, please visit http://www.nyxoah.com/.

Caution – CE marked since 2019. Investigational device in the United States. Limited by U.S. federal law to investigational use in the United States.

Contacts:
Nyxoah
David DeMartino, Chief Strategy Officer
david.demartino@nyxoah.com
+1 310 310 1313

Attachment

• ENGLISH – Analyst Meeting Save the Date_FINAL

GlobeNewswire Distribution ID 1000783964

London, U.K., Feb. 13, 2023 (GLOBE NEWSWIRE) — OPEN Health, a pre-eminent global provider of scientific communications and HEOR & market access services, announced the acquisition of Acsel Health (“Acsel”), a New York-based life science strategy and advisory firm focused on commercial strategy, pricing and market access, and commercial excellence.

Acsel’s deep industry expertise, scientific rigor, and actionable analysis drives its success in providing valued partnership to life science companies. These capabilities will complement OPEN Health’s existing offering, broadening the range of services it offers to pharma and biotech companies.

Lujing Wang, Managing Partner of Acsel Health, said, “We are thrilled to join OPEN Health and to work with a wider team to solve for today’s demands and meet tomorrow’s expectations for pharma and biotech customers. With new colleagues and capabilities to partner with, we are equipped to answer the most challenging cross-disciplinary questions in life science across all key therapeutic areas.”

“Acsel is an extraordinary addition to OPEN Health. Acsel’s expert team and long-standing client relationships significantly strengthen our ability to support the commercialization of our clients’ assets and unlock access for patients.” said OPEN Health CEO, Rob Barker. “We are excited to welcome Acsel Health into the OPEN Health Group and look forward to working with our new colleagues to offer our clients innovative, scientific solutions around the globe.”

Fairmount Partners acted as exclusive financial advisor to Acsel Health. The terms of the transaction were not disclosed.

About OPEN Health

OPEN Health unites deep scientific knowledge with wide-ranging specialist expertise to unlock possibilities that improve health outcomes and patient wellbeing. Working in partnership with our clients, we embrace our different perspectives and strengths to deliver fresh thinking and solutions that make a difference. OPEN Health is a flexible global organization that solves complex healthcare challenges across HEOR and market access, medical communications and creative omnichannel campaigns. For more information on OPEN Health, visit www.openhealthgroup.com.

About Acsel Health

Acsel Health is a consulting firm that partners with renowned life science companies to guide life-changing innovations through their critical stages, from early development through market maturity. Acsel applies best-practice principles to develop and deliver highly individualized solutions to challenges across the product lifecycle for our clients. For more information on Acsel Health, visit www.acselhealth.com.

Attachment

• OPEN Health to acquire leading US-based life science strategy and advisory firm Acsel Health

Candice Subero
OPEN Health
candicesubero@openhealthgroup.com

GlobeNewswire Distribution ID 8744608

Carl D Francis takes the helm at medtech group focused on reversal of diabetes, NASH, and obesity

LONDON, Feb. 07, 2023 (GLOBE NEWSWIRE) — Today Keyron, the medical technology group focused on reversing type 2 diabetes, non-alcoholic steatohepatitis (NASH), and obesity via an innovative medical device platform, announced the appointment of Carl D Francis as Chief Executive Officer.

“The continuing rise in obesity, diabetes, and all forms of fatty liver disease is one of the biggest health challenges the world faces today. Literally billions of people are affected, and the numbers continue to rise rapidly,” Francis said. “Keyron’s technology is a complete game-changer. An innovative, non-surgical, endoscopically-delivered, fully reversible treatment as an alternative to drastic bariatric surgeries is as exciting as it gets. I am really proud and honoured to be part of Keyron.”

The American Diabetes Association states that today 37m Americans suffer from diabetes, with 96m having pre-diabetes. The link between obesity and diabetes is well established, and according to The World Obesity Federation’s forecast in their recently released 2022 Atlas, 67% of women and 51% of men in the Americas will be living with obesity (BMI ≥ 30) by 2030.

Keyron’s patented technology is designed to be a fully endoscopic, outpatient procedure providing the same or greater metabolic benefits of gastric bypass surgery, including a reversal of type 2 diabetes and obesity, as well as NASH and liver fibrosis.

Following successful rodent studies in 2019 and swine studies in 2022, Keyron’s first-in-human trials are planned to begin in early 2024. Keyron is targeting to achieve FDA clearance by 2028, and a US launch is planned as the first target market. The company is now making plans to raise a $15m Series A funding round.

Dr Giorgio Castagneto Gissey, Keyron’s Chairman, said, “We are thrilled that Carl will be leading Keyron as we enter this critical stage of our development. Carl brings energy, focus, and senior leadership experience to ensure we realize our full potential. Keyron has always had high profile, world-leading board members and medical advisors, and we continue to bring onboard remarkable people. We are truly delighted to have been able to attract Carl.”

Francis was previously CEO of successful nano-technology group P2i. During his tenure the group grew from a handful of employees to global leadership in the functional nano-coating space. He was most recently CEO of UK-based medtech group Eyoto which specializes in advanced technologies in the optical and ophthalmic industries. He started his career as a US CPA, is a member of Mensa, and has a BSc from the University of Cincinnati.

CONTACT

For further information please contact:

• In the USA – Carl D Francis at c.francis@keyron.com or +1 (912) 429-3800
• In Europe – Dr Giorgio Castagneto Gissey at gcgissey@keyron.com or +44 7975 911101

ABOUT KEYRON

Keyron is a UK-based, preclinical-stage medical device and technology platform company aimed at a highly-effective treatment of metabolic diseases. Keyron’s patented ForePass is an innovative medical device designed to safely reverse type-2 diabetes, as well as NASH, and obesity. The company has already demonstrated a full reversal of insulin resistance in animal studies, and recently published the results in The Lancet EBioMedicine. Keyron has upcoming clinical trials in South America and aims to then carry out further clinical trials in the USA. Its founders, directors, advisors and investors include some of the most well-known and cited professors and KOLs worldwide in the metabolic diseases space. The company is backed by multiple institutional investors based in the USA and EMEA.

GlobeNewswire Distribution ID 8743797

• Jean-Christophe Gallagher appointed Executive Vice President, Aircraft Sales and Bombardier Defense
• Paul Sislian appointed Executive Vice President of Bombardier Aftermarket Services & Strategy
• David Murray appointed Executive Vice President, Manufacturing, IT and Bombardier Operational Excellence System
• Eric Filion joins Bombardier to the newly created role of Executive Vice President, Programs and Supply Chain
• Michel Ouellette will lead Engineering and Product Development until planned retirement later in 2023, following a 33-year, successful career

MONTREAL, Feb. 06, 2023 (GLOBE NEWSWIRE) — Bombardier today announced a leadership team evolution that will focus on carrying forward the company’s positive momentum toward executing long-term growth and optimization strategies in the key areas of defense, services, continuous product improvement and next-generation manufacturing practices.

“Bombardier has successfully embarked on its journey as a company focused on its world-class business jet portfolio. As we continue to meet or exceed targets, it is the right time to thoughtfully reshape key leadership functions to ensure the solid foundation we have set fully carries our momentum well into the future,” said Éric Martel, President and CEO, Bombardier. “Our leadership team members are talented and have delivered on commitments time and again these past years, and this new alignment will further build upon the foundations they have successfully set for Bombardier.”

As part the leadership structure evolution, the following alignments and appointments will take effect on February 20, and all other existing Bombardier leadership team members will continue in their roles:

Jean-Christophe Gallagher is appointed Executive Vice President, Aircraft Sales & Bombardier Defense. Gallagher will lead all aspects of Bombardier’s growing defense business as its product offering and customer base expand. Gallagher will also oversee the talented Sales team led by Peter Likoray, Senior Vice President, New Aircraft Sales. Under Peter’s leadership, Bombardier has grown its backlog and built local roots across the world. Peter will continue to deepen his and his team’s passion for crafting unique experiences for Bombardier customers as they match their discerning needs to the company’s exceptional portfolio.

Paul Sislian is appointed Executive Vice President, Bombardier Aftermarket Services & Strategy. Having spent 15 years optimizing and leading Bombardier’s business jet manufacturing facilities and processes, Sislian will now carry forward and accelerate the division’s strategic growth journey that saw Bombardier inaugurate four newly built or expanded maintenance facilities around the world in 2022.

All aerostructures, assembly and completions activities will be led by David Murray, who will add these responsibilities to his current mandates and is appointed to the role of Executive Vice President, Manufacturing, IT and Bombardier Operational Excellence System (BOE). The alignment of these three functions will enable a new focus on availing teams of next-generation digital technologies to further enhance Bombardier core processes.

Éric Filion is appointed to the new role of Executive Vice President, Programs and Supply Chain. In this capacity, Filion will oversee all Bombardier supplier relationships and lead continuous, competitive improvement efforts for all in-production Bombardier aircraft. Filion previously held operations and program leadership positions at Bombardier, including oversight of the Challenger aircraft production facility. Most recently he served as Executive Vice President, Chief Operating and Customer Experience Officer for Hydro-Québec. Filion will join Bombardier on February 20, 2023.

Finally, Michel Ouellette will lead Engineering and Product Development as the group’s Executive Vice President. After a 33-year career at Bombardier that culminated in the successful certification of the Global 7500 jet and subsequent launch of the performance-leading Global 8000 flagship aircraft, Ouellette is set to retire at the end of June 2023.

“Michel’s contributions to Bombardier can certainly be enumerated at great length, and their positive and lasting impact on our people, our products and our company is simply immeasurable,” said Martel. “On behalf of everyone at Bombardier whose lives Michel has touched, I want to sincerely thank him for his leadership and passion—and wish him all the best in his next chapter. I also look forward to continuing collaborating in the months ahead, as we press forward with exciting projects.”

About Bombardier
Bombardier (BBD-B.TO) is a global leader in aviation, focused on designing, manufacturing, and servicing the world’s most exceptional business jets. Bombardier’s Challenger and Global aircraft families are renowned for their cutting-edge innovation, cabin design, performance, and reliability. Bombardier has a worldwide fleet of approximately 5,000 aircraft in service with a wide variety of multinational corporations, charter and fractional ownership providers, governments, and private individuals. Bombardier aircraft are also trusted around the world in government and military special-mission roles leveraging Bombardier Defense’s proven expertise.

Headquartered in Greater Montréal, Québec, Bombardier operates aerostructure, assembly and completion facilities in Canada, the United States and Mexico. The company’s robust customer support network services the Learjet, Challenger and Global families of aircraft, and includes facilities in strategic locations in the United States and Canada, as well as in the United Kingdom, Germany, France, Switzerland, Italy, Austria, the UAE, Singapore, China and Australia.

For corporate news and information, including Bombardier’s Environmental, Social and Governance report, as well as the company’s plans to cover all its flight operations with Sustainable Aviation Fuel (SAF) utilizing the Book and Claim system visit bombardier.com. Learn more about Bombardier’s industry-leading products and customer service network at businessaircraft.bombardier.com. Follow us on Twitter @Bombardier.

Bombardier, Global, Global 7500, Global 8000 and Challenger are registered or unregistered trademarks of Bombardier Inc. or its subsidiaries.

For Information
Mark Masluch
Bombardier
+1-514-855-7167

GlobeNewswire Distribution ID 8743397

Cryotec Anlagenbau GmbH Wurzen Germany

Cryotec Anlagenbau GmbH Wurzen Germany

TEMECULA, Calif., Feb. 06, 2023 (GLOBE NEWSWIRE) — Nikkiso Clean Energy and Industrial Gases Group (“Group”), a part of Nikkiso Co., Ltd (Japan), and operating under Cryogenic Industries, Inc. (USA), completed the acquisition of Cryotec Anlagenbau GmbH (Cryotec), located in Wurzen, Saxony, Germany for an undisclosed amount.

A global plant engineering and construction company, Cryotec provides planning, project management, manufacturing, and engineering services of skid-mounted/containerized air separation and liquefaction plants, and CO2 technologies offering tailored solutions to their customers.

Cryotec will operate as part of the Group’s GmbH facility, based in Neuenburg am Rhine, Germany.

The Group consists of six functional business units: Cryogenic Pumps, Heat Exchanger Systems, Process Systems, Fueling & Solutions, Energy Infrastructure & Strategic Projects, and Service. Cryotec will be acting as the Nikkiso Clean Energy and Industrial Gases Group competence and production center in Europe.

“Nikkiso will promote and sell globally the intelligent packaged solutions from Cryotec that reduce and recover carbon dioxide emissions, and further support the sustainability goals of the Group. Cryotec will have full access to the innovative technologies developed in California and elsewhere in the Nikkiso Group and offer localized packages, solutions, and stations for LH2 (Liquid Hydrogen) LNG (Liquefied Natural Gas), ammonia, and cryogenic energy storage applications within Germany and Europe. We will support the growth of Cryotec, by adding resources and increasing our manufacturing and assembly activities in Saxony and supplying Cryotec solutions to Germany and the global market”, according to Peter Wagner, CEO of Cryogenic Industries and President of the Group.

Prime Minister of Saxony, Michael Kretschmer stated: “The acquisition of Cryotec Anlagenbau by Nikkiso strengthens the internationalization of a traditional Saxon company from Wurzen. Nikkiso has global experience in renewable energy, hydrogen, and energy storage. Renewable energies and green hydrogen play a key role in achieving the energy and climate targets in Saxony. The Free State of Saxony is already an important location for the research and application of hydrogen technologies. I am delighted that Nikkiso will contribute its expertise to Saxony in the future.”

“Nikkiso will be able to assist with this project realization as well as the supply and servicing of liquid hydrogen and LNG filling stations in the European Market”, according to Ole Jensen, Vice President, Europe. “This acquisition represents our commitment to and support the European Union targets to be climate-neutral by 2050.”

The purchase was effective February 3, 2023.

ABOUT Nikkiso Clean Energy & Industrial Gases Group
Nikkiso Clean Energy & Industrial Gases Group is part of the Industrial Division of Nikkiso co. Lt. Japan. The Group operates in the US, under Cryogenic Industries, Inc. (a member of Nikkiso Co., Ltd.). The Group member companies manufacture, and service engineered cryogenic gas processing equipment (pumps, turboexpanders, heat exchangers, etc.), and process plants for Industrial Gases, Natural Gas Liquefaction (LNG), Hydrogen Liquefaction (LH2) and Organic Rankine Cycle for Waste Heat Recovery. Founded over 50 years ago, Cryogenic Industries is the parent company of ACD, Nikkiso Cryo, Nikkiso Integrated Cryogenic Solutions, Cosmodyne and Cryoquip and a commonly controlled group of approximately 20 operating entities.

For more information, please visit www.NikkisoCEIG.com and www.nikkiso.com.

MEDIA CONTACT:
Anna Quigley
+1.951.383.3314
aquigley@cryoind.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/5818ee3c-2c93-4ad0-b03b-a87bda21cfce

GlobeNewswire Distribution ID 8743139